Views & Analysis

Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions. The COVID-19 pandemic led to

Why reshoring drug production means embracing continuous manufacturing

https://pharmaphorum.com/market-access-2/why-reshoring-drug-production-means-embracing-continuous-manufacturing/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Philips on designing innovation and cultivating partnerships – part two

Jessica Hagen collaboration, pharma, Philips, Philips Africa, Philips India 0 Comment

This article follows part one of our two-part series, where we discussed how Philips designs innovation and digital

Philips on designing innovation and cultivating partnerships – part two

https://pharmaphorum.com/market-access-2/philips-on-designing-innovation-and-cultivating-partnerships-part-two/

Market Access/ Views & Analysis/ Views and analysis

Global comparator data signal “alarm bells” for UK Government, says APBI

Amanda Barrell ABPI, clinical trial recruitment, clinical trials, Life Sciences, UK life sciences, UK market access 0 Comment

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Despite the UK’s

Global comparator data signal “alarm bells” for UK Government, says APBI

https://pharmaphorum.com/market-access-2/global-comparator-data-signal-alarm-bells-for-uk-government-says-apbi/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Philips on designing innovation and cultivating partnerships – part one

Jessica Hagen healthcare access, India, Philips India, Phillips, Sachin Grover, telehealth 0 Comment

Sachin Grover, lead of solutions vertical at Philips India, tells me about the company’s innovations during India’s COVID

Philips on designing innovation and cultivating partnerships – part one

https://pharmaphorum.com/market-access-2/philips-on-designing-innovation-and-cultivating-partnerships-part-one/

Market Access/ Views & Analysis/ Views and analysis

The new European Unitary Patent system – What you need to know

mike.hammerton@pharmaphorum.com European Union, European Unitary Patent system 0 Comment

The proposed European unitary patent and unified patent court represents one of the largest changes to the European

The new European Unitary Patent system – What you need to know

https://pharmaphorum.com/market-access-2/the-new-european-unitary-patent-system-what-you-need-to-know/

Market Access/ Views & Analysis/ Views and analysis

As FDA inspections return, upholding compliance and maintaining GMP readiness is more crucial than ever

mike.hammerton@pharmaphorum.com Dipti Gulati, fda, good manufacturing practice, NSF Health Sciences, Pharmaceutical Quality systems 0 Comment

The pharmaceutical industry has long been highly regulated to help ensure quality and safety across all aspects of

As FDA inspections return, upholding compliance and maintaining GMP readiness is more crucial than ever

https://pharmaphorum.com/market-access-2/fda-inspections-return-maintaining-gmp-readiness-is-more-crucial-than-ever/

Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

The big squeeze?

Leela Barham Cancer Drugs Fund, NHS, NHS Digital, NHS spending 0 Comment

With NHS England highlighting savings of £1.2 billion on medicines in three years coming from both deals on

The big squeeze?

https://pharmaphorum.com/market-access-2/the-big-squeeze/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Are timely access and robust safety mutually exclusive?

Amanda Barrell EFPIA, ema, fda, Kristina Jenei, Oncology 0 Comment

The FDA approves new cancer treatments in half the time of the EMA – but does faster mean

Are timely access and robust safety mutually exclusive?

https://pharmaphorum.com/market-access-2/are-timely-access-and-robust-safety-mutually-exclusive/

Market Access/ Views & Analysis/ Views and analysis

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

mike.hammerton@pharmaphorum.com COVID-19, IQVIA, launch excellence, pandemic, Sarah Rickwood 0 Comment

The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. COVID

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

https://pharmaphorum.com/market-access-2/pharmas-post-pandemic-launch-performance-problem/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Views & Analysis

Login